Hertility Health, the new women’s health start-up revolutionising the world of hormone and reproductive health, today announces the closing of a £4.2m Seed funding round led by LocalGlobe – one of the UK’s most prolific seed investors, Venrex, and some key angel investors including former CEO of Bupa, Evelyn Bourke, CEO of Nested and the unicorn company GoCardless, Matt Robinson.
The funds will help Hertility Health expand its current product offering of fertility and hormone testing, menopause, miscarriage, postnatal care, polycyctic ovarian syndrome (PCOS) and endometriosis testing, as well as aid the expansion of its current clinical trials which aim to reduce the diagnosis time for some of the most common reproductive conditions. This cash injection will also work towards establishing Hertility Health as a leading scientific and clinical educational health hub for women in a sector that’s set to be worth $50bn by 2025.
“We live in a society that expects us to tolerate pain and mask our symptoms. Some women spend over ten years on their contraception, never fully knowing if there might be something wrong”, says Hertility Health CEO and Founder, Dr Helen O’Neill. On average, 1 in 5 Hertility Health users have been found to have a previously undiagnosed reproductive condition which has been revealed as a result of testing with Hertility Health.
Mark Esiri of Venrex Investment Management, commented: “Venrex tries to find creative entrepreneurs who often have ‘differences of opinion’ with the status quo. This has been a common thread at companies we have been lucky enough to back, including Revolut, Charlotte Tilbury, Mumsnet, NotOnTheHighStreet and Maven Clinic. WE are very fortunate to be working with the Hertility Health team who are bringing world class technical expertise, a data-driven approach and relentless energy to address deeply important health issues. We believe that these bright and passionate founders can use their expertise to positively change the world.”